Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan-Mar;47(1):103738.
doi: 10.1016/j.htct.2025.103738. Epub 2025 Feb 15.

Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization

Affiliations

Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization

Mehmet Bakırtaş et al. Hematol Transfus Cell Ther. 2025 Jan-Mar.

Abstract

Introduction: Granulocyte colony-stimulating factor (G-CSF) is the most prevalently used growth factor for peripheral blood hematopoietic stem cell (HSC) mobilization. Most centers split the granulocyte colony-stimulating factor in two daily doses, whereas some centers administer one dose per day. This study aims to investigate the effect of the filgrastim dosing schedule on the quantity of hematopoietic stem cells collected after mobilization in healthy donors.

Methods: A total of 251 healthy donors mobilized in our center were included in the study. Mobilization was either once a day (filgrastim 1 × 10 mg/kg/day) or twice a day (filgrastim 2 × 5 mg/kg/day).

Results: White blood cell and peripheral CD34+ cell numbers were significantly higher in the Twice-a-day Group on the fifth day compared to the Once-a-day Group. No statistically significant difference was shown between the two groups regarding the number of CD34+ cells collected on the first apheresis day or the number of apheresis procedures needed to achieve the targeted number of CD34+ cells.

Conclusion: This study revealed that one daily dose of 10 mg/kg filgrastim is as effective as administering the same dose split on two days for an adequate amount of CD34+ cells in healthy donors.

Keywords: Filgrastim; G-CSF; Hematopoietic stem cell mobilization; Posology.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

Similar articles

References

    1. Dreger P., Haferlach T., Eckstein V., Jacobs S., Suttorp M., Löffler H., et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994;87:609–613. - PubMed
    1. Bensinger W.I., Weaver C.H., Appelbaum F.R., Rowley S., Demirer T., Sanders J., et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995;85:1655–1658. - PubMed
    1. Horowitz M., Confer L. American Soc of Hematol Program Book; 2005. Evaluation of Hematopoietic Stem Cell Donors; pp. 469–475. - PubMed
    1. Stiff P.J. Management strategies for the hard-to-mobilize patient. Bone Marrow Transpl. 1999;23(Suppl. 2):29–33. - PubMed
    1. Takeyama K., Ohto H. Peripheral stem cell mobilization. Transfus Apher Sci. 2004;31(3):233–243. - PubMed

LinkOut - more resources